Literature DB >> 8810665

Induction by chronic autoimmune arthritis in DBA/1 mice by oral administration of type II collagen and Escherichia coli lipopolysaccharide.

K Terato1, X J Ye, H Miyahara, M A Cremer, M M Griffiths.   

Abstract

We have developed a new model of autoimmune arthritis in DBA/1 mice by feeding chick type II collagen (CII) for 2-3 week intervals over a 15 week period. Clinically evident arthritis occurred in 8/10 mice receiving native CII (nCII; 100 micrograms/mouse) alone at 9-13 weeks. Arthritis was aggravated by the further ingestion of CII, while remission occurred after withdrawal of the CII. Heat-denatured CII (dCII; 200 micrograms/mouse) was also arthritogenic if co-administered with ovoinhibitor (OVI; 2 mg/mouse), a proteinase inhibitor. Co-oral administration of lipopolysaccharide (LPS; 10 micrograms/mouse) with CII enhanced the antibody production and T-cell responses to CII, and induced a more chronic arthritis that progressed spontaneously without further administration of CII or LPS. Long-term oral administration of LPS alone also induced a mild arthritis characterized by destruction of bone rather than cartilage. These observations suggest that abnormal gastrointestinal absorption of dietary mimic antigens and intestinal bacterial toxins can potentially disrupt self-tolerance mechanisms, thereby precipitating or exacerbating autoimmune disease in genetically susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8810665     DOI: 10.1093/rheumatology/35.9.828

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  17 in total

1.  Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity.

Authors:  Arno Hänninen; Nathan R Martinez; Gayle M Davey; William R Heath; Leonard C Harrison
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 2.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Bacterial lipopolysaccharide acts as an adjuvant to induce autoimmune arthritis in mice.

Authors:  S Yoshino; E Sasatomi; M Ohsawa
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

4.  Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation.

Authors:  Shahla Abdollahi-Roodsaz; Leo A B Joosten; Marije I Koenders; Ben T van den Brand; Fons A J van de Loo; Wim B van den Berg
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

5.  Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide.

Authors:  Nathan R Martinez; Petra Augstein; Antonis K Moustakas; George K Papadopoulos; Silvia Gregori; Luciano Adorini; David C Jackson; Leonard C Harrison
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

6.  Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans?

Authors:  Arno Hanninen; Leonard C Harrison
Journal:  Rev Diabet Stud       Date:  2004-11-10

7.  Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes.

Authors:  Kutty Selva Nandakumar; Lars Svensson; Rikard Holmdahl
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

8.  Correlation between Yersinia enterocolitica and type I collagen reactivity in patients with arthropathies.

Authors:  María G Lacoste; Héctor Tamashiro; Silvia G Correa; Ana M S de Guzmán; María S Di Genaro
Journal:  Rheumatol Int       Date:  2006-12-02       Impact factor: 3.580

9.  Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxins: results of an open-labelled pilot study.

Authors:  Kou Katayama; Takeo Matsuno; Takaki Waritani; Kuniaki Terato; Hiroshi Shionoya
Journal:  Nutr J       Date:  2011-01-06       Impact factor: 3.271

Review 10.  Rheumatoid arthritis viewed using a headache paradigm.

Authors:  R Holmdahl
Journal:  Arthritis Res       Date:  2000-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.